XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 33.23

+0.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thomas J Pittman who wrote (7822)	11/25/1998 1:54:00 AM
From: aknahow	Read Replies (1) of 17367

Agree the market is indifferent. This is IMO a non event. It only becomes important if Neuprex is approved and does result in significant sales outside of the U.S. If Neuprex fails the P III trial the stock will drop and lawyers will be all over trying encourage a shareholders suit. Even in that case I would prefer Bermuda because the suits produce nothing for shareholders but lots for the lawyers and, guess what, non approval is part of the risk involved in buying biotech stocks. Non approval does not, automatically, mean management, screwed the shareholders. Thousands of companies including Shell and Esso make use of Bermuda. Check out the link, provided earlier. Do any shareholders care that XOMA a company with its' offices and manufacturing plants in California is registered as a Delaware corporation?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next